Unlock AI-driven, actionable R&D insights for your next breakthrough.

Polycaprolactone: Comprehensive Analysis Of Synthesis, Properties, And Biomedical Applications

MAR 23, 202656 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Polycaprolactone (PCL) is a semi-crystalline, biodegradable aliphatic polyester synthesized primarily via ring-opening polymerization of ε-caprolactone monomers. With a melting point of 59–64°C 2,8,10 and a glass transition temperature of approximately −60°C 2,6,10, PCL exhibits exceptional flexibility, processability, and biocompatibility, making it a cornerstone material in tissue engineering, drug delivery, and sustainable packaging. Its structural repeating unit—comprising five non-polar methylene groups (—CH₂—) and one polar ester group (—COO—)—confers both hydrophobic character and mechanical ductility 2,5,16. This article provides an in-depth examination of PCL's molecular architecture, synthesis methodologies, physicochemical properties, and diverse applications, targeting advanced R&D professionals seeking to optimize PCL-based systems for next-generation biomedical and industrial solutions.
Want to know more material grades? Try Patsnap Eureka Material.

Molecular Composition And Structural Characteristics Of Polycaprolactone

Polycaprolactone is defined by its linear aliphatic polyester backbone, with the repeating unit formula —(CO—O—CH₂—CH₂—CH₂—CH₂—CH₂—)ₙ— 2,5,16. This structure arises from the ring-opening polymerization of ε-caprolactone, a seven-membered cyclic ester, under catalysis by metal-organic compounds such as tetraphenyltin or coordination catalysts 2,5. The polymer's semi-crystalline nature (crystallinity typically 40–50% 6) results from the regular packing of methylene sequences, while the ester linkages introduce polarity and sites for hydrolytic degradation 10,16.

Key Structural Features:

  • Methylene-to-Ester Ratio: The five methylene groups per ester bond yield a relatively hydrophobic polymer with low water uptake, yet the ester groups enable biodegradation via hydrolysis 2,5.
  • Molecular Weight Range: Commercial PCL typically exhibits number-average molecular weights (Mₙ) from 40,000 to 100,000 g/mol 16, though synthesis conditions can yield Mₙ values from 7,000 to over 50,000 g/mol depending on catalyst and initiator choice 5,12,14. Weight-average molecular weights (Mw) can reach 100,000–200,000 g/mol 13, with polydispersity indices reflecting the control achieved during polymerization.
  • Thermal Properties: PCL's melting point (Tm) is consistently reported at 59–64°C 2,6,8,10, and its glass transition temperature (Tg) at −60 to −62°C 2,6,10, conferring rubbery elasticity at ambient and physiological temperatures. These low transition temperatures facilitate melt processing and solvent-free fabrication techniques 10.

Functional Group Modifications:

Recent advances have introduced multifunctionalized PCL variants bearing amino, hydroxyl, or epoxy groups 3,12. For example, multifunctionalized bioactive PCL with at least two amino groups per chain has been synthesized to enhance cell adhesion and bioactivity 3. Similarly, carboxyl-terminated PCL prepared via reaction with anhydrides enables conjugation with fluorinated acrylate polymers for hydrophobic surface modification 2. Hydroxyl-terminated PCL precursors are also reacted with fumaric acid to yield polycaprolactone fumarate (PCLF), a cross-linkable derivative suitable for nerve conduits and bone scaffolds 12.

Synthesis Routes And Catalytic Systems For Polycaprolactone Production

Ring-Opening Polymerization Mechanisms

Ring-opening polymerization (ROP) of ε-caprolactone is the dominant industrial route, offering superior control over molecular weight and minimizing side reactions compared to polycondensation of 6-hydroxycaproic acid 5. ROP proceeds via anionic, cationic, or coordination mechanisms, with coordination catalysts (e.g., tin(II) octoate, aluminum alkoxides) being most prevalent due to their high activity and tolerance to functional groups 5,14.

Catalyst Selection And Performance:

  • Organotin Catalysts: Tetraphenyltin and tin(II) octoate are widely used but raise concerns regarding cytotoxicity from residual tin 5. Bulk polymerization at 130–150°C with tin catalysts yields PCL with Mₙ ≈ 50,000–80,000 g/mol 5.
  • Metal-Organic Framework (MOF) Catalysts: Novel zinc-containing isopoly-molybdic acid MOFs have been reported to catalyze bulk ROP of ε-caprolactone with high thermal stability and reproducibility, achieving weight-average molecular weights exceeding 50,000 g/mol without alcohol initiators 5,14. These catalysts offer reduced toxicity and simplified purification, addressing regulatory concerns for biomedical applications 5,14.
  • Initiator Systems: Dihydroxy or trihydroxy compounds (e.g., ethylene glycol, glycerol, pentaspiroglycol) serve as initiators, controlling chain length and introducing terminal hydroxyl groups for further functionalization 1,9. For instance, pentaspiroglycol-initiated PCL polyols exhibit improved stain resistance in polyurethane elastomers 9.

Process Conditions:

Typical bulk ROP is conducted at 150–180°C under inert atmosphere (nitrogen or argon) to prevent oxidative degradation 1,5. Reaction times range from 2 to 6 hours, with catalyst loadings of 0.1–0.5 wt% relative to monomer 5,14. Post-polymerization, residual monomer is removed by vacuum stripping, and the polymer is pelletized for downstream processing 1.

Copolymerization Strategies

PCL is frequently copolymerized with other lactones or lactides to tailor degradation kinetics and mechanical properties:

  • Poly(lactide-co-caprolactone) (PLCL): Copolymers with 10–25 mol% ε-caprolactone units exhibit enhanced ductility and slower degradation than pure polylactide, with weight-average molecular weights of 200,000–500,000 g/mol 13,15. PLCL is used in electrospun meshes for drug delivery and tissue scaffolds 11,15.
  • Poly(glycolide-co-caprolactone) (PGCL): Incorporation of glycolide accelerates hydrolytic degradation, useful for short-term implants 7,15.
  • Block Copolymers: PCL-PEG-PCL triblock copolymers form micelle-like nanostructures in aqueous media, enabling drug encapsulation and controlled release 6. PEG segments (Mₙ ≈ 2,000–20,000 g/mol) confer hydrophilicity and stealth properties, reducing opsonization 6,19.

Physicochemical Properties And Performance Metrics Of Polycaprolactone

Mechanical And Thermal Characteristics

PCL's mechanical profile is characterized by moderate tensile strength, high elongation at break, and low modulus, making it suitable for flexible biomedical devices:

  • Tensile Strength: Typically 10–25 MPa for neat PCL films, depending on molecular weight and crystallinity 10. Blending with poly(succinic acid-adipic acid-butanediol) copolyester or grafted glycidyl methacrylate can enhance tensile strength to 30–40 MPa 1.
  • Elongation At Break: 300–800%, reflecting the polymer's ductility and toughness 10,12. This extensibility is critical for applications requiring mechanical compliance, such as vascular grafts and nerve conduits 12.
  • Elastic Modulus: 0.2–0.4 GPa, lower than polylactide (2–4 GPa) but sufficient for load-bearing scaffolds when reinforced with fillers (e.g., hydroxyapatite, talc) 1,10.
  • Thermal Stability: Thermogravimetric analysis (TGA) shows onset of degradation at approximately 350°C, with complete decomposition by 450°C under nitrogen 5. Differential scanning calorimetry (DSC) confirms Tm at 60°C and crystallization temperature (Tc) at 30–35°C 2,6.

Solubility And Processing Behavior

PCL is soluble in a wide range of organic solvents, including chloroform, dichloromethane, tetrahydrofuran, and hexafluoro-2-propanol (HFIP), facilitating solution-based fabrication techniques such as electrospinning, solvent casting, and nanoprecipitation 2,10,18. Its low melting point enables melt extrusion, injection molding, and 3D printing at temperatures below 100°C, minimizing thermal degradation and energy consumption 1,4,10.

Melt Viscosity: At 150°C, PCL melt viscosity ranges from 500 to 2,000 Pa·s (at shear rates of 10–100 s⁻¹), depending on molecular weight 1. Addition of plasticizers (e.g., glycerin, sorbitol) reduces viscosity and improves film-blowing processability 1.

Biodegradation Kinetics And Mechanisms

PCL undergoes hydrolytic degradation via random scission of ester bonds, yielding ε-hydroxycaproic acid oligomers that are metabolized via the tricarboxylic acid cycle or excreted renally 10,12. Degradation is autocatalytic, accelerated by acidic byproducts, and proceeds more slowly than poly(lactic-co-glycolic acid) (PLGA) due to PCL's hydrophobicity and high crystallinity 4,10.

Degradation Rates:

  • In Vitro: Mass loss of 10–20% over 6 months in phosphate-buffered saline (PBS, pH 7.4, 37°C) for PCL films (thickness 100–200 μm) 10,12. Molecular weight decreases exponentially, with Mₙ halving in 3–4 months 12.
  • In Vivo: Complete resorption of PCL scaffolds in rat subcutaneous implants occurs over 12–24 months, with macrophage-mediated phagocytosis of low-molecular-weight fragments 10,12. Coating with polydopamine (pDA) accelerates surface mineralization and bone-bonding, reducing resorption time to 6–12 months 4.

Acidification Concerns: PLGA degradation generates lactic and glycolic acid, causing local pH drops (pH 4–5) that induce inflammation and cytotoxicity 8. PCL's slower degradation mitigates acidification, but copolymers with glycolide may still require buffering agents (e.g., magnesium hydroxide) to neutralize acidic byproducts 8.

Applications Of Polycaprolactone In Biomedical Engineering

Tissue Engineering Scaffolds And Regenerative Medicine

PCL's biocompatibility, tunable degradation, and processability make it a leading scaffold material for bone, cartilage, nerve, and vascular tissue engineering 4,10,12,15.

Bone Regeneration:

PCL scaffolds are often mineralized with hydroxyapatite or coated with polydopamine to enhance osteoconductivity 4. For example, PCL-pDA-pMAA (polymethacrylic acid) composites exhibit bone-like apatite formation in simulated body fluid (SBF) within 7 days, with compressive moduli of 50–100 MPa 4. Three-dimensional printed PCL scaffolds with 60% porosity and 400 μm pore size support osteoblast proliferation and differentiation, achieving bone ingrowth of 40–60% in rabbit femoral defects over 12 weeks 4,10.

Nerve Conduits:

Polycaprolactone fumarate (PCLF) nerve conduits (inner diameter 1.5 mm, wall thickness 0.5 mm) support robust axonal regeneration across 10 mm rat sciatic nerve defects, with nerve conduction velocities recovering to 70–80% of normal by 12 weeks post-implantation 12. PCLF's cross-linkable nature allows in situ curing and mechanical matching to native nerve tissue (tensile modulus 5–10 MPa) 12.

Cartilage Repair:

Electrospun PCL nanofibers (diameter 200–800 nm) seeded with chondrocytes and cultured in chondrogenic medium produce cartilage-like extracellular matrix with glycosaminoglycan content of 15–25 μg/mg scaffold and collagen type II expression comparable to native cartilage 8,10. Addition of magnesium hydroxide (5–10 wt%) neutralizes acidic degradation products, maintaining pH 7.0–7.4 and reducing cytotoxicity 8.

Vascular Grafts:

PCL-PEG-PCL triblock copolymer tubes (inner diameter 4 mm, wall thickness 0.8 mm) exhibit burst pressures of 1,500–2,000 mmHg and suture retention strengths of 2–3 N, meeting requirements for small-diameter vascular grafts 6. PEG segments reduce platelet adhesion and thrombosis, with patency rates of 60–70% in rat aortic interposition models over 8 weeks 6.

Drug Delivery Systems And Controlled Release

PCL nanoparticles, micelles, and films enable sustained release of hydrophobic and hydrophilic drugs over weeks to months 10,18,19.

Nanoparticle Formulations:

PCL nanoparticles (diameter 100–300 nm) prepared by nanoprecipitation encapsulate chemotherapeutics (e.g., docetaxel, camptothecin, etoposide) with loading efficiencies of 60–80% and release 50–70% of payload over 30 days in vitro 18. PEGylation of PCL nanoparticles increases circulation half-life from 2–4 hours to 12–24 hours in mice, enhancing tumor accumulation via the enhanced permeability and retention (EPR) effect 19.

Electrospun Meshes:

Poly(lactic acid-co-caprolactone) (90:10 molar ratio) electrospun meshes loaded with anti-inflammatory (e.g., 5-aminosalicylic acid) or antimicrobial agents (e.g., silver nanoparticles) release 40–60% of drug over 14 days, with zero-order kinetics suitable for wound dressings and post-surgical adhesion prevention 11,18.

Implantable Depots:

PCL rods (diameter 3 mm, length 10 mm) containing aripiprazole (antipsychotic) or isradipine (antihypertensive) provide steady-state plasma concentrations for 3–6 months in rats, reducing dosing frequency and improving patient compliance 18.

Sustainable Packaging And Industrial Applications

PCL's biodegradability and compatibility with conventional plastics enable its use in compostable films, adhesives, and coatings 1,13,16.

Biodegradable Films:

PCL blended with modified starch (oxidized or hydroxypropyl starch, 20–40 wt%) and poly(succinic acid-adipic acid-butanediol) copolyester (20–40 wt%) yields films with tensile strength of 25–35 MPa, elongation at break of 400–600%, and water vapor transmission rates (WVTR) of 50–80 g/m²/day, suitable for food packaging 1. Addition of waterproofing agents (e.g., beeswax, epoxidized soybean oil, 5–10 wt%) reduces WVTR to 20–40 g/m²/day 13.

Home Compostable Blends:

PCL (30–50 wt%) blended with polyglycolic acid (PGA, 30–50 wt%) and polyhydroxyalkanoates (PHA, 10–20 wt%) disintegrates in home compost (25–30°C, 60% humidity) within 90–120 days

OrgApplication ScenariosProduct/ProjectTechnical Outcomes
NANJING WURUI BIODEGRADABLE NEW MATERIAL RESEARCH INSTITUTE CO. LTD.Biodegradable packaging films for food applications requiring good mechanical strength, water resistance, and compostability.PCL Modified Starch-Based Biodegradable ResinBlending PCL with poly(succinic acid-adipic acid-butanediol) copolyester and modified starch achieves tensile strength of 25-35 MPa, elongation at break of 400-600%, and film-blowing at 150-178°C with improved mechanical performance and water resistance.
UNIVERSIDADE DO MINHOBone regeneration scaffolds, injectable bone adhesives, and implants requiring osteoconductivity and mechanical matching to native bone tissue.PCL-pDA-pMAA Bone AdhesivePolycaprolactone coated with polydopamine and polymethacrylic acid exhibits bone-like apatite formation in simulated body fluid within 7 days, compressive moduli of 50-100 MPa, and enhanced biomineralization promoting bone-bonding.
Mayo Foundation for Medical Education and ResearchPeripheral nerve repair, segmental nerve defect reconstruction, and tissue engineering applications requiring cross-linkable, biocompatible scaffolds with controlled degradation.Polycaprolactone Fumarate (PCLF) Nerve ConduitsPCLF nerve conduits (1.5 mm inner diameter, 0.5 mm wall thickness) support robust axonal regeneration across 10 mm rat sciatic nerve defects with nerve conduction velocities recovering to 70-80% of normal by 12 weeks, releasing no diethylene glycol during degradation.
Changzhou UniversityIndustrial-scale production of high-molecular-weight polycaprolactone for biomedical applications, drug delivery systems, and tissue engineering scaffolds requiring low-toxicity synthesis routes.Zinc-Containing Isopoly-Molybdic Acid MOF CatalystNovel metal-organic framework catalyst enables bulk ring-opening polymerization of ε-caprolactone without alcohol initiators, achieving weight-average molecular weights exceeding 50,000 g/mol with high thermal stability, reproducibility, and reduced cytotoxicity compared to organotin catalysts.
BASF SESustainable packaging materials, compostable films, and single-use products requiring home compostability, biodegradability, and compatibility with conventional plastic processing equipment.PCL-PGA-PHA Home Compostable BlendBlending polycaprolactone (30-50 wt%) with polyglycolic acid (30-50 wt%) and polyhydroxyalkanoates (10-20 wt%) achieves complete disintegration in home compost (25-30°C, 60% humidity) within 90-120 days while maintaining mechanical integrity during use.
Reference
  • Polycaprolactone modified starch-based biodegradable resin material and preparation method thereof
    PatentInactiveAU2020227123A1
    View detail
  • Fluorine-containing polycaprolactone film and preparation method therefor
    PatentActiveUS20210079184A1
    View detail
  • Multifunctionalized bioactive polycaprolactone
    PatentActiveUS20190134209A1
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png